Clinical trial
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian…
NCT00327444 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00327444 |
|---|---|
| Title | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites |
| Official title | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-arm Study of the Effect of Intravenous Aflibercept Administered Every 2 Weeks in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Regeneron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms, Ascites |
| Intervention type | Drug |
| Interventions | aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Placebo |
| Enrollment | 58 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | May 18, 2006 |
| Last update posted | Jan 1, 2013 |
| Countries | Austria, Belgium, Canada, Hungary, India, Israel, Spain, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: